Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort
Status:
Completed
Trial end date:
2017-05-04
Target enrollment:
Participant gender:
Summary
This study will investigate whether switching symptomatic COPD patients from a fixed-dose
combination of salmeterol/fluticasone 50/500 µg b.i.d. to a fixed dose combination of QVA149
110/50 µg o.d. leads to improved lung function and airflow. It will also assess the effect on
symptom burden, breathlessness, and use of rescue medication after this switch.